2026-06-29T02:09:51Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1043692025-03-18T12:31:54Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Rodríguez Cobos, Alfredo author Atencia Fernández, Sabela María author 2023-07-25 A 2-year-old, neutered, female beagle was presented to a referral hospital for investigation of pancytopenia. The patient had a history of recurrent infections and, on previous blood tests, anaemia, leukopenia and thrombocytopenia were detected. At the time of presentation, the patient had been treated for 2 weeks with omeprazole, amoxicillin-clavulanic acid, marbofloxacin and gabapentin, and for 3 months with prednisolone, in decreasing doses. A bone marrow aspirate and core biopsy were performed. Hypoplastic bone marrow was observed. Once underlying infectious diseases and exposure to toxins were ruled out, a diagnosis of aplastic anaemia was made. The patient was treated with eltrombopag, a thrombopoietin receptor agonist that stimulates primitive haematopoietic stem cells, used for the treatment of aplastic anaemia in humans. One week after starting eltrombopag treatment, all the affected cellular lines were recovered. The patient continued in remission 7 months after treatment. Rodriguez-Cobos A, Atencia S. Aplastic anaemia treated using eltrombopag in a dog. Vet Rec Case Rep. 2023; 11:e675. https://doi.org/10.1002/vrc2.675 10.1002/vrc2.675 https://hdl.handle.net/20.500.14352/104369 2052-6121 https://doi.org/10.1002/vrc2.675 Aplastic anaemia treated using eltrombopag in a dog